

7

FORM PTO-1449 (Modified)		Attorney Docket No.: 15270-004740US		Application No.: 09/322,289		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Dale B. Schenk				
		Filing Date: May 28, 1999		Group: 1648		
Reference Designation		U.S. PATENT DOCUMENTS				Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<u>SO</u> AA	5,877,399	3/2/99	Hsiao et al.			
<u>SO</u> AB	5,837,473	11/17/98	Maggio et al.			
<u>SO</u> AC	5,851,996	12/22/98	Kline			
<u>SO</u> AD	5,753,624	5/19/98	McMichael et al.			
<u>SO</u> AE	5,612,486	3/18/97	McConlogue et al.			
<u>SO</u> AF	5,679,348	10/21/97	Nesburn et al.			
<u>SO</u> AG	5,605,811	2/25/97	Seubert et al.			
<u>SO</u> AH	5,220,013	6/15/93	Ponte et al.			
<u>SO</u> AI	5,208,036	5/4/93	Eppstein et al.			
<u>SO</u> AJ	5,057,540	10/15/91	Kensil et al.			
<u>SO</u> AK	4,666,829	5/19/85	Glenner et al.			
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
<u>SO</u> AL	WO 99/27949	6/10/99	PCT			
<u>SO</u> AM	WO 98/44955	10/15/98	PCT			
<u>SO</u> AN	0 868 918	10/7/98	Europe			
<u>SO</u> AO	0 526 511 B1	5/28/97	EP			
<u>SO</u> AP	WO 97/17613	5/15/97	PCT			
<u>SO</u> AQ	WO 95/11311	4/27/95	PCT			
<u>SO</u> AR	WO 95/05853	3/2/95	PCT			
<u>SO</u> AS	WO 94/01772	1/20/94	PCT			
<u>SO</u> AT	WO 92/13069	8/6/92	PCT			
<u>SO</u> AU	2 220 211 A	1/4/90	GB			
<u>SO</u> AV	WO 89/03687	5/5/89	PCT			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
<u>SO</u> AW	Borchelt et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins", <u>Neuron</u> , 19: 939-945 (October 1997).					
<u>SO</u> AX	Boris-Lawrie et al., "Recent advances in retrovirus vector technology", <u>Cur. Opin. Genet Develop.</u> , 3: 102-109 (1993).					
<u>SO</u> AY	Duff et al., "Mouse model made", <u>Nature</u> , 373: 476-477 (1995)					
<u>SO</u> AZ	Elizan et al., "Antineurofilament antibodies in a postencephalitic and idiopathic parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).					
<u>SO</u> BA	Games et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein", <u>Nature</u> , 373(6514): 523-527 (February 9, 1995).					
<u>SO</u> BB	Gaskin et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (April 1993).					
<u>SO</u> BC	Glenn et al., "Skin immunization made possible by cholera toxin", <u>Nature</u> , 391: 851 (1998).					

EORM PTO-1449 (Modified)		Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Dale B. Schenk	Group: 1648
BD	Glenner et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein", <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (May 16, 1994).		
BE	Glenner et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein", <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (August 16, 1984).		
BF	Gupta et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs", <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).		
BG	Hanes et al., "New advances in microsphere-based single-dose vaccines", <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).		
BH	Hardy, "Amyloid, the presenilins and Alzheimer's disease", <u>TINS</u> , 20(4): 154-159 (1997).		
BI	Hsiao et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice", <u>Science</u> , 274: 99-102 (October 4, 1996).		
BJ	Jansen et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity", <u>Immun. Rev.</u> , 62: 185-216 (1982).		
BK	Langer, "New Methods of Drug Delivery", <u>Science</u> , 249: 1527-1532 (September 28, 1990).		
BL	Livingston et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection", <u>J. Immunol.</u> , 159: 1383-1392 (1997).		
BM	Lopez et al., "Serum auto-antibodies in Alzheimer's disease", <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).		
BN	McGee et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility", <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).		
BO	Nathanson et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic", <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).		
BP	Paresce et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor", <u>Neuron</u> , 17:553-565 (September 1996).		
BQ	Paul et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers", <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).		
BR	Prieels et al., "Synergistic adjuvants for vaccines", <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (February 21, 1994).		
BS	Selkoe, "Alzheimer's Disease: A Central Role for Amyloid", <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (September 1994).		
BT	Selkoe, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease", <u>Trends in Neurosciences</u> , 16(10): 403-409 (October 1993).		
BU	Seubert et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <u>Nature</u> , 359: 325-327 (September 24, 1992).		
BV	Smits et al., "Prion Protein and Scrapie Susceptibility", <u>Vet. Quart.</u> , 19(3): 101-105 (September 1997).		
BW	Stoute et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria", <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997).		
BX	Sturchler-Pierrat et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology", <u>Proc. Natl. Acad. Sci USA</u> , 94: 13287-13292 (November 1997).		
BY	Weissmann et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease", <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997).		
BZ	Wood et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease", <u>Proc. Natl. Acad. Sci USA</u> , 94: 1550-1555 (February 1997).		
EXAMINER <i>[Signature]</i>		DATE CONSIDERED 10-6-03	


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#8

FORM PTO-1449 (Modified)		Attorney Docket No.: 15270-004740US		Application No.: 09/322,289	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Dale B. Schenk			
		Filing Date: May 28, 1999		Group: 1648	
Reference Designation		U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Sub-class	Filing Date (If Appropriate)
AA	5,958,883	9/28/99	Snow		
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Sub-class	Translation (Yes/No)
AB	EP 276 723	12/8/93	Europe		Yes
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
AC	Solomon, A., "Pro Rx (Protein Therapeutics)," University of Tennessee Medical Center				No date improper format
AD	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee.				improper format no date
EXAMINER	DATE CONSIDERED		6-13-01		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#9

FORM PTO-1449 (Modified)		Attorney Docket No.: 15270-004740US		Application No.: 09/322,289	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Dale B. Schenk			
		Filing Date: May 28, 1999		Group: 1648	
Reference Designation		Page 1			
U.S. PATENT DOCUMENTS					
Examiner Initial	Document No.	Date	Name	Class	Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Translation (Yes/No)
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
<u>SB</u> AA	Lemere et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, 10/23-28/99.				
<u>SB</u> AB	Raso, V.A., "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (4/2/98).				
<u>SB</u> AC	Solomon et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).				
<u>SB</u> AD	Solomon et al., "Monoclonal antibodies inhibit in <i>vitro</i> fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).				
EXAMINER			DATE CONSIDERED <u>10-6-03</u>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

11

FORM PTO-1449 (Modified)		Attorney Docket No.: 15270J-004740US		Application No. 001,222,289	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Dale B. Schenk		Group: 1648	
		Filing Date: May 28, 1999		NOV 07 2001	
Reference Designation U.S. PATENT DOCUMENTS					
Examiner Initial	Document No.	Date	Name	Class	Sub-class
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Sub-class
AA	WO 99/27911	6/10/99	PCT		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
AB	Selkoe, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).				
AC	Wengenack et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-824 (2000).				
EXAMINER <i>S. J. J. J.</i> DATE CONSIDERED 6-13-01					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.